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Abstract. Toxocariasis is a preventable parasitic disease that is caused by the dog and cat roundworms Toxocara cani
and T. cati, respectively. Humans become infected when they accidently ingest infectious Toxocara eggs commonly found
in contaminated soil; children are most often affected. Clinical manifestations of Toxocara infection in humans include
ocular toxocariasis and visceral toxocariasis. Although infection with Toxocara can cause devastating disease, the burden
of toxocariasis in the United States population remains unknown. In addition, risk factors for acquiring infection need
to be better defined, and research needs to be conducted to better understand the pathophysiology and clinical course
of toxocariasis. Development of diagnostic tests would enable clinicians to detect active infection, and determination
of optimal drug regiments would ensure patients were appropriately treated. Addressing these public health gaps
is necessary to understand and address the impact of toxocariasis in the United States.
BACKGROUND
Toxocariasis, a parasitic disease caused by dog roundworms
(Toxocara canis), cat roundworms (T. cati). or possibly other
species of Toxocara, can lead to debilitating disease in
humans and mainly affects children. Studies have shown that
toxocariasis may be among the most common human parasitic
infections in the United States.1 It is estimated that millions
of Americans have been exposed to the Toxocara parasite,
although how many persons have become ill from the infec-
tion is unknown.2 Toxocariasis is considered a neglected par-
asitic infection, and few resources have been devoted to
increasing public and healthcare provider awareness of this
preventable disease. In addition, research towards increasing
epidemiologic knowledge, improving diagnostic tests, and defin-
ing optimal treatment regimens for toxocariasis remains limited.
Transmission of the Toxocara parasite occurs when an
infected dog or cat sheds eggs in their feces into the environ-
ment; it takes 2–4 weeks for larvae to develop and for the eggs
to become infectious.3 Toxocara eggs are typically found in
soil contaminated with dog or cat feces; humans become
infected when they accidentally ingest the microscopic eggs,
usually through touching contaminated hands to their mouth.
Children are at higher risk for infection because of their play
habits and poor hygiene practices. Although less common,
humans can also become infected if they eat undercooked
meat from an animal that is infected with Toxocara larvae.
Once ingested, the larvae can burrow into and travel through
blood vessels to various body organs causing an inflammatory
reaction; in humans, Toxocara larvae do not undergo further
growth or maturation into adult worms.
There are three well-described clinical presentations of
Toxocara infection in humans; visceral toxocariasis (VT) or
visceral larva migrans, when body organs, such as the liver or
lungs, are affected; ocular toxocariasis (OT) or ocular larva
migrans, when the eye is affected; and covert or common
toxocariasis, when symptoms remain mild and non-specific.
Liver and pulmonary damage are the most commonly described
clinical complications in VT patients; other less common disease
manifestations caused by Toxocara infection include neuro-
toxocariasis, eosinophilic meningitis, pericardial effusion, and
myocarditis.4–8 In OT patients, inflammation caused by
Toxocara larvae can cause severe, irreversible ophthalmologic
injury, such as retinal detachment or formation of a subretinal
granulomatous mass or scar; unilateral permanent vision loss
develops in many OT patients.
Eosinophilia, hypergammaglobulinemia, and increased
isohemagglutinin A and B titers are laboratory findings asso-
ciated with acute Toxocara infection. Laboratory abnormali-
ties are less likely to be found in OT patients than in VT
patients. Serologic antibody tests to the Toxocara parasite
are available in laboratories throughout the United States.
The recommended test for toxocariasis is an enzyme immuno-
assay (EIA) using Toxocara excretory–secretory antigens to
detect IgG against the Toxocara larvae. In patients with a
presumptive diagnosis of toxocariasis, sensitivity of the
Toxocara EIA is reported to be 78% and 73% for VT and
OT, respectively, and the specificity of the test is > 90% for
VT and OT at a titer ³ 1:32.9 EIA titers can remain elevated
for years, making it difficult to determine if a positive sero-
logic test result indicates past exposure verses active infection.
Stool examination for ova and parasites is not useful in diag-
nosing Toxocara because the larvae do not mature into adult
worms and therefore no eggs are shed.
Albendazole or mebendazole are the recommended treat-
ments for Toxocara infection although these drugs are not
approved by the Food and Drug Administration for this indi-
cation.10 To date, no randomized controlled treatment studies
have been conducted in the United States and questions
remain surrounding the optimum drug dose and duration of
therapy; most clinicians prescribe a five-day treatment course,
although there are reports of 20-day drug courses being used
in patients with severe symptoms. Corticosteroids are benefi-
cial in reducing inflammation and are often recommended as
adjunctive therapy especially in severe VT cases and in most
OT cases. No recommendations exist for treating asymptom-
atic patients who have positive serologic test results; what long-
term clinical sequelae may arise from untreated Toxocara
infection is unknown. Prevention strategies include teaching
children not to eat soil, promoting good hand washing hygiene,
and covering sandboxes when not in use. Pets should be regu-
larly dewormed and communities should urge residents to keep
pets away from playground areas and require pet owners to
properly dispose of their pet’s feces.
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PUBLIC HEALTH IMPORTANCE OF TOXOCARIASIS
IN THE UNITED STATES
Toxocariasis is a completely preventable disease and
although reports of devastating disease occurring in patients
continue to be published in the scientific literature, little
research has been devoted to understanding the extent of
burden caused by infection with Toxocara within the United
States population. Toxocariasis is not a nationally reportable
disease and no surveillance systems are currently in place to
track cases. In an effort to quantify how many persons have
been infected with Toxocara in the United States, a nationally
representative seroprevalence survey was conducted during
1988–1994.11 Testing of samples collected during the Third
National Health and Nutrition Examination Survey demon-
strated that Toxocara seroprevalence was 13.9% in the U.S.
population ³ 6 years of age. Non-Hispanic blacks (21%) had
significantly higher positive seroprevalence rates than non-
Hispanic whites (12%). Multiple studies consistently report
that the disease primarily affects children; the average age
of VT patients is 2–7 years and the average age of OT patients
is 8–16 years12,13 National Health and Nutrition Examination
Survey data for children 6–11 years of age demonstrates a
difference in Toxocara seroprevalence rates; 15% in black
girls, 20% in black boys, and < 5% in white children. Epide-
miologic research has shown associations between Toxocara
and increased blood lead levels, lower education status, and
poverty.11 Other risk factors for Toxocara infection, such as
geophagia, pet ownership, and living in warmer climates, have
been identified but there is variability in the significance of
these relationships among different studies.14,15 An associa-
tion between Toxocara and toxoplasmosis, another neglected
parasitic infection, was highlighted in one study in which
infection with one of the parasites was associated with almost
twice the risk of infection with the other parasite compared
with those who were not dually infected.16
Determining the prevalence and incidence of VT is
extremely challenging because the clinical manifestations are
nonspecific, leading to under-recognition of cases by health
professionals. A review of VT case reports in the literature for
1952–1972 documented 970 VT cases in western countries.17
Most current data on VT is obtained through small retrospec-
tive cohort studies and case reports; these reports highlight
the wide range of clinical disease attributed to Toxocara
infection, including respiratory, gastrointestinal, and neuro-
logic illnesses. Although rare, Toxocara infection has led to
death in adult and pediatric VT patients.18–20
Toxocara infection has also been linked to diminished lung
function, cognitive changes, and adverse neuropsychological
effects.21,22 Questions remain surrounding the link between
asthma and allergic symptoms, such as urticaria and infection
with Toxocara. Studies have shown a decrease in forced
expiratory volume in one second in persons infected with
Toxocara compared with those without infection.23 A sepa-
rate study that tested children with asthma for Toxocara anti-
bodies found no significant association between asthma and
Toxocara infection.24 Given the enormous numbers of chil-
dren with asthma in the United States and its attendant eco-
nomic burden, there is a strong need to clarify the association
between asthma and Toxocara infection.
Research on the prevalence of OT is limited and has been
conducted only in single ophthalmologic centers; based on a
survey of ophthalmologists in Alabama, the prevalence of OT
was estimated to be 1 case/1,000 persons.25 In a separate study
conducted in California, the investigators estimated that 1.0%
of persons with vision loss had Toxocara infection as the
cause.13 In a recent national survey of ophthalmologic subspe-
cialists, 559 respondents reported 68 cases of OT in children
within one year; the median patient age was 8.5 years, and
68% of patients with reported clinical data experienced per-
manent vision loss.26
Studies have shown that Toxocara is widespread in the
environment and throughout the dog and cat population in
the United States. Soil sample testing for Toxocara eggs in
public parks and sandboxes, has demonstrated rates ranging
from 0.3% to 39%.27,28 In dog and cat fecal samples tested
during 2013, data collected from national laboratories showed
that 1.8% of tested pet dogs were positive for Toxocara infec-
tion and 4.7% of tested pet cats were positive for Toxocara
infection.29 A recent survey examining more than one million
canine fecal samples taken from dogs at veterinary clinics
in the United States showed a Toxocara prevalence rate
of 2.2%; rates were even higher (6.5%) in puppies less than
six months old.30 A separate study that examined feline fecal
samples in cats residing in two shelter in New York demon-
strated a T. cati prevalence rate of 21%, indicating that
shelter animals may have higher prevalence rates than
household pets.31
GAPS IN CURRENT KNOWLEDGE
AND FUTURE DIRECTIONS
The most critical knowledge gap needing to be addressed
for toxocariasis remains defining the true impact of the dis-
ease in the United States through population-based studies;
without this baseline information it is difficult to determine
the level of resources that should be devoted to this infection.
Defining the economic costs incurred by toxocariasis would
also assist in this decision-making process. Prevalence and
incidence rate data also need to be monitored over time in an
effort to assess the effectiveness of prevention strategies and
success of treatment interventions.
Efforts also need to be focused on better defining the epi-
demiologic characteristics of toxocariasis cases and the demo-
graphics of affected groups. Further exploration into the
differences in risk for infection among minority populations,
as well as regional variations, and differences in disease prev-
alence in urban versus rural settings. The results of these
studies will enable us to target risk behaviors and direct pre-
vention messages to high risk groups.
Numerous questions remain surrounding the pathophysiol-
ogy and clinical manifestations of the disease. Why some
patients remain asymptomatic or have nonspecific self-limited
symptoms and severe clinical manifestations develop in others
is not fully understood. In addition, why VT develops in some
patients and others have only OT remains unknown. Long-
term medical consequences of Toxocara infection, such as
asthma and neurocognitive delays, should be a research prior-
ity. Initiating large-scale prospective studies aimed at defining
the spectrum of clinical disease will help us to answer these
questions. One of the major barriers to collecting toxocariasis
prevalence data and clinical information is that many
healthcare providers are not familiar with the disease, leading
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to missed diagnosis in patients infected with Toxocara.
Education of healthcare providers regarding toxocariasis
is a priority.
Presently, diagnostic testing for Toxocara infection is
limited to antibody testing, which cannot differentiate current
active disease and past infection. Development of a test that
can accurately diagnose recent infection will help clinicians
confirm active Toxocara infection in patients and potentially
lead to initiation of treatment to prevent clinical disease. No
randomized controlled trials of treatment medications have
been conducted; current treatment guidelines are based on
clinician experience and expert opinion. Drug trials to deter-
mine the optimal therapeutic agent and ideal dosage and
duration of therapy are needed. Advances in ophthalmologic
surgical techniques may help decrease the number of patients
with permanent vision loss caused by OT. Studies need to be
conducted to determine if persons who are asymptomatic but
seropositive for Toxocara need to be treated.
Because toxocariasis is a zoonotic disease, increasing our
knowledge about how the disease affects dogs and cats is cru-
cial in preventing animal and human infection. Questions have
been raised regarding anthelminthic drug resistance in dogs
and cats.32 In addition, the challenge of getting pet owners to
have their dogs and cats tested and treated appropriately for
Toxocara remains.
Although further investigation is needed to guide public
health and clinical recommendations, there are steps that can
be taken right now. For example, coverage of programmatic
interventions focused on reduction of prevalence in animals
and prevention of transmission to humans should be
improved. Educational campaigns directed at the general
public and healthcare professionals would help to increase
awareness about toxocariasis. Working with veterinarians to
increase pet owners’ understanding of the importance of fre-
quent deworming and the need to properly dispose of their
pet’s feces will also help highlight this neglected parasitic
infection. An increase in our understanding of this devastat-
ing yet preventable disease, coupled with improved disease
control efforts, will ultimately lead to a decrease in disease
burden in humans and animals.
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